Moreover, the 36-month beta value for RGC is 2.59. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for RGC is 30.40M and currently, short sellers hold a 2.50% of that float. On June 16, 2025, RGC’s average trading volume was 12.43M shares.
RGC) stock’s latest price update
Regencell Bioscience Holdings Ltd (NASDAQ: RGC)’s stock price has gone rise by 203.31 in comparison to its previous close of 15.66, however, the company has experienced a 182.05% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-06 that ROANOKE, Va., May 06, 2025 (GLOBE NEWSWIRE) — RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $7,676,208, or $0.74 per share, for the second quarter ended March 31, 2025, compared to $6,443,390, or $0.63 per share, for the second quarter ended March 31, 2024. The primary drivers of the increased earnings were higher base rates that went into effect July 1, 2024 and increased volumes, offset by lower earnings from unconsolidated affiliate and higher interest expense.
RGC’s Market Performance
Regencell Bioscience Holdings Ltd (RGC) has experienced a 182.05% rise in stock performance for the past week, with a 349.00% rise in the past month, and a 9656.76% rise in the past quarter. The volatility ratio for the week is 2.24%, and the volatility levels for the past 30 days are at 14.21% for RGC. The simple moving average for the past 20 days is 176.77% for RGC’s stock, with a 1915.66% simple moving average for the past 200 days.
RGC Trading at 440.70% from the 50-Day Moving Average
After a stumble in the market that brought RGC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 90.00% of gains for the given period.
Stock Fundamentals for RGC
The total capital return value is set at -0.29. Equity return is now at value -42.49, with -40.85 for asset returns.
Currently, EBITDA for the company is -3.62 million with net debt to EBITDA at 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 41.92.
Conclusion
To wrap up, the performance of Regencell Bioscience Holdings Ltd (RGC) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
